Journal Article

DKFZ-2024-00784

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Low tumor interleukin-1β expression predicts a limited effect of adjuvant platinum-based chemotherapy for patients with completely resected lung adenocarcinoma: An identification and validation study.

Safi, S. ; Krzykalla, J.DKFZ* ; Hoffmann, H. ; Benner, A.DKFZ* ; Bischoff, H. ; Eichhorn, M. ; Kriegsmann, M. ; Poschke, I. ; Stögbauer, F. ; Umansky, L.DKFZ* ; Mogler, C. ; Weichert, W. ; Winter, H. ; Beckhove, P. ; Muley, T.

2024
Elsevier Amsterdam

This record in other databases:  

Please use a persistent id in citations: doi:10.1016/j.pulmoe.2024.03.003

Abstract: Adjuvant platinum-based chemotherapy for completely resected non-small cell lung cancer is associated with modest improvement in survival; nevertheless, no validated biomarker exists for predicting the benefit or harm of adjuvant platinum-based chemotherapy.We simultaneously measured 27 cytokines in operative tumor specimens from a discovery cohort (n = 97) by multiplex immunoassay; half of the patients received adjuvant platinum-based chemotherapy, and the other half were observed. We tested possible prognostic and predictive factors in multivariate Cox models for overall survival (OS) and relapse-free survival (RFS), and a tree-based method was applied to detect predictive factors with respect to RFS. The results were validated in an independent validation cohort (n = 93).Fifty-two of 97 (54 %) patients in the discovery cohort and 50 of 93 (54 %) in the validation cohort received adjuvant chemotherapy; forty-four (85 %) patients in the discovery cohort and 37 (74 %) in the validation cohort received four cycles as planned. In patients with low IL-1β-expressing tumors, RFS and OS were worse after adjuvant chemotherapy than after observation. The limited effect of adjuvant chemotherapy for patients with low IL-1β-expressing tumors was confirmed in the validation cohort. Additionally, RFS and OS were prolonged by adjuvant chemotherapy only in patients with high IL-1β-expressing tumors in the validation cohort.This study identified and validated low tumor IL-1β expression as a potential biomarker of a limited response to adjuvant platinum-based chemotherapy after complete resection of pulmonary adenocarcinoma. This finding has the potential to inform adjuvant treatment decisions.

Keyword(s): Biomarkers ; Cytokines ; IL-1β ; Lung neoplasms ; Tumor microenvironment

---

Contributing Institute(s):

1. C060 Biostatistik (C060)
2. KKE Dermatoonkologie (A370)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2024

---

Database coverage:
; ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---